3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Solid Tumors Harboring NTRK Fusion
2
Sarcoma
2
Neoplasms
2
Tumors Harboring NTRK Fusion
1
Thyroid Neoplasms
1
Salivary Gland Neoplasms
1
Melanoma
1
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
1
Interventions
Gemcitabine
27
Cisplatin
24
pembrolizumab
15
durvalumab
12
Fluorouracil
11
Capecitabine
10
Oxaliplatin
9
Leucovorin
8
Bevacizumab
7
Carboplatin
5
Paclitaxel
4
Nivolumab
4
Irinotecan
4
Injections
4
zanidatamab
3
trametinib
3
lenvatinib
3
derazantinib
3
atezolizumab
3
Ramucirumab
3
Docetaxel
3
tremelimumab
2
surufatinib
2
pertuzumab
2
gemcitabine-oxaliplatin regimen
2
envafolimab
2
Trastuzumab
2
S 1 (combination)
2
Itraconazole
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biliary Tract Neoplasms
×
larotrectinib
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA